TRANSCEND-T2D-1: Retatrutide vs Insulin for Diabetes

TRANSCEND-T2D-1 is one of the most consequential trials in the retatrutide program. It compares retatrutide directly to insulin — the current last-resort treatment for type 2 diabetes — in a head-to-head study. Phase 2 data showed retatrutide reduced A1C by up to 2.02% while producing significant weight loss (Jastreboff et al., NEJM 2023), while insulin typically controls blood sugar at the cost of substantial weight gain. If TRANSCEND demonstrates that retatrutide can match insulin's glycemic control while causing weight loss instead of weight gain, it could fundamentally change how type 2 diabetes is managed.

The Insulin Paradox

Insulin is a life-saving medication for diabetes, but it comes with a cruel paradox: the treatment for a disease largely caused by excess weight causes more weight gain. On average, patients starting insulin gain 4-8 pounds in the first year, and weight gain continues over time. This creates a vicious cycle:

• Excess weight causes insulin resistance, leading to diabetes
• Insulin treatment controls blood sugar but causes weight gain
• Weight gain worsens insulin resistance, requiring higher insulin doses
• Higher doses cause more weight gain

Retatrutide breaks this cycle by controlling blood sugar through entirely different mechanisms while simultaneously producing dramatic weight loss.

Retatrutide vs Insulin: Expected Comparison

TRANSCEND-T2D-1 Design

• Population: Adults with type 2 diabetes inadequately controlled on non-insulin medications
• Comparator: Basal insulin (the standard next step in diabetes treatment)
• Primary endpoint: A1C reduction (non-inferiority or superiority to insulin)
• Key secondary endpoints: Weight change, hypoglycemia rates, cardiovascular markers, patient satisfaction
• Duration: 52-72 weeks

What TRANSCEND Means for Patients

If TRANSCEND demonstrates that retatrutide is at least as effective as insulin for blood sugar control with the added benefit of significant weight loss, the implications are enormous:

• New treatment algorithm: Retatrutide could become the preferred next step before insulin, rather than the current last-resort position of GLP-1 drugs
• Quality of life: Once-weekly injections vs. daily insulin, no daily blood sugar monitoring, weight loss instead of gain
• Disease modification: Weight loss could put diabetes into remission, potentially allowing patients to reduce or stop all diabetes medications
• Insurance coverage: Head-to-head superiority over insulin would strongly support insurance coverage

Effective Diabetes Treatment Available Now

GLP-1 medications are already used as insulin alternatives for many patients:

• Compounded semaglutide: $99/month
• Compounded tirzepatide: $125/month

Learn more about how to get started.